{"id":4631,"date":"2026-10-07T10:08:34","date_gmt":"2026-10-07T04:38:34","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-07\/"},"modified":"2026-10-07T17:29:17","modified_gmt":"2026-10-07T11:59:17","slug":"alkem-share-price-today-2026-10-07","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-07\/","title":{"rendered":"Alkem Laboratories Share Price Today: Why ALKEM Is Rising 1.11% | 7 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: ALKEM<\/strong> \u00b7 7 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b95,350.50<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+1.11%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b95,403.00 \/ \u20b95,293.50<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b95,292.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>1.97 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>7 October 2026 \u00b7 03:15 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Alkem Laboratories Ltd. shares are trading higher by 1.11% at \u20b95,350.50 on the NSE, moving within a day&#x27;s range of \u20b95,293.50 and \u20b95,403.00 after opening at \u20b95,365.50.<\/li>\n<li>Alkem Laboratories informed the exchange that it has issued a corporate guarantee amounting to Euro 54.45 million to HSBC UK Bank plc. This guarantee backs a term loan of Euro 49.5 million availed by M\/s. Occlutech Holding AG, a step-down subsidiary of the company in Switzerland. The company noted that this represents a contingent liability that would become payable only if the subsidiary defaults.<\/li>\n<li>Trading volume was 1.29 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Alkem Laboratories share price rising on 7 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Alkem Laboratories Ltd. shares are trading higher by 1.11% at \u20b95,350.50 on the NSE, moving within a day&#x27;s range of \u20b95,293.50 and \u20b95,403.00 after opening at \u20b95,365.50.<\/p>\n<p class=\"wt-copy\">The broader market sentiment was subdued as the Nifty slipped 0.76% and the Nifty Pharma sector benchmark declined by 0.43%, reflecting relative outperformance by the stock against its sectoral peers. The equity has also posted a positive return of 1.91% over the trailing 5 trading days and 3.27% over the past 20 trading days.<\/p>\n<p class=\"wt-copy\">While no single immediate exchange filing was published today to trigger the session&#x27;s gains, the company recently announced the launch of NeuCeno (cenobamate) for the treatment of partial-onset seizures on September 16, 2026, and a corporate guarantee of Euro 54.45 million issued for its Swiss subsidiary Occlutech Holding AG on September 21, 2026. These developments provide ongoing strategic context rather than a direct catalyst for today&#x27;s price action.<\/p>\n<p class=\"wt-copy\">1.97 lakh shares traded by 7 October 2026 \u00b7 03:15 PM IST. This compares with a 20-day average daily volume of 1.52 lakh shares (1.29 times). The five-day average daily volume was 1.70 lakh shares. Separately, the NSE report for 6 October 2026 showed 33,361 shares delivered, representing 52.40% of that day\u2019s traded volume. The same report recorded 10,111 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Stock-specific buying amid sector divergence<\/strong><\/p>\n<p class=\"wt-copy\">The move appears driven by stock-specific accumulation and above-average cash volume rather than a confirmed same-day news catalyst, outperforming a weak broader pharmaceutical sector.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Corporate Guarantee Issued for Swiss Subsidiary<\/div>\n<div class=\"wt-card-date\">21 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Alkem Laboratories informed the exchange that it has issued a corporate guarantee amounting to Euro 54.45 million to HSBC UK Bank plc. This guarantee backs a term loan of Euro 49.5 million availed by M\/s. Occlutech Holding AG, a step-down subsidiary of the company in Switzerland. The company noted that this represents a contingent liability that would become payable only if the subsidiary defaults.<\/p>\n<p class=\"wt-copy\">It establishes a notable financial commitment and contingent liability supporting the international expansion and capital requirements of its step-down subsidiary.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_21092026173921_Reg_30_disclosure_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Launch of NeuCeno (cenobamate) in India<\/div>\n<div class=\"wt-card-date\">16 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced the commercial launch of NeuCeno (cenobamate) as an anti-seizure medication for adult patients suffering from partial-onset seizures. Being introduced for the first time in India, the once-daily oral therapy aims to address the significant healthcare burden of epilepsy by offering a dual mechanism of action.<\/p>\n<p class=\"wt-copy\">Expanding into specialized chronic therapies like neurology strengthens Alkem&#x27;s product portfolio in high-unmet-need segments beyond its core acute offerings.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Resignation of Chief Financial Officer<\/div>\n<div class=\"wt-card-date\">24 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Alkem Laboratories disclosed that Mr. Nitin Agrawal resigned from his position as Chief Financial Officer and Key Managerial Personnel on July 30, 2026, to pursue new professional opportunities, with his cessation taking effect from September 30, 2026. The required regulatory disclosures regarding the change in senior management were duly submitted to the stock exchanges.<\/p>\n<p class=\"wt-copy\">Leadership transitions in key financial roles require monitoring for continuity in corporate governance, financial reporting, and strategic execution.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">16 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated September 16, 2026, titled &quot;Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Management \/ board update<\/div>\n<div class=\"wt-card-date\">24 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Change in Key Managerial Personnel Resignation of Chief Financial Officer.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_24092026124110_Reg30Intimation_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">49.70%<\/div>\n<div class=\"wt-note\">51.20% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">10.42%<\/div>\n<div class=\"wt-note\">10.16% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">33.05%<\/div>\n<div class=\"wt-note\">31.56% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 29 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Mutual Fund &#8211; Hdfc Mid-Cap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">57.07 lakh shares \u00b7 4.77%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Icici Prudential Multi-Asset Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">42.68 lakh shares \u00b7 3.57%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Large &amp; Midcap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">23.83 lakh shares \u00b7 1.99%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">17 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Neutral<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b95,770.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a neutral stance with a target price of \u20b95,770 following Q1 earnings results that featured a profit beat.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">JAYANTI SINHA<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 12.38 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 9.04 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">SAMPRADA&amp;NANHAMATI SINGH FAMILY TRUST<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 5.50 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 5.10 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution progress and adoption rates following the launch of NeuCeno (cenobamate) in domestic neurology markets<\/li>\n<li>Updates on the transition and appointment process for the Chief Financial Officer following the cessation of Mr. Nitin Agrawal<\/li>\n<li>Performance trends in key chronic and specialty therapeutic segments in upcoming financial results<\/li>\n<li>Sustained cash-market volume and delivery percentage relative to the 20-day average volume of 1.29x<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-01\/\">Why Alkem Laboratories Shares Fell 2.24% Today: Sector Trends in Focus | 1 October 2026 \u2014 1 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-09-30\/\">Why Alkem Laboratories Shares Fell 1.65% Today: Sector Trends | 30 September 2026 \u2014 30 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/alkem\/\">More Alkem Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Alkem Laboratories company news?<\/h3>\n<p class=\"wt-copy\">Alkem Laboratories informed the exchange that it has issued a corporate guarantee amounting to Euro 54.45 million to HSBC UK Bank plc. This guarantee backs a term loan of Euro 49.5 million availed by M\/s. Occlutech Holding AG, a step-down subsidiary of the company in Switzerland. The company noted that this represents a contingent liability that would become payable only if the subsidiary defaults.<\/p>\n<h3>How strong was Alkem Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">1.97 lakh shares traded, 1.29 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 \u00b7 03:15 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-07\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-07\/\"}, \"headline\": \"Alkem Laboratories Share Price Today: Why ALKEM Is Rising 1.11% | 7 October 2026\", \"description\": \"Alkem Laboratories share price rose 1.11% to \u20b95,350.50 today. See why ALKEM is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-07T04:38:34Z\", \"dateModified\": \"2026-10-07T17:29:06.516730+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/alkem-company-news-2026-10-07.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"summary\":\"a press release dated September 16, 2026, titled \\\"Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.\\\".\",\"category\":\"Press Release\",\"date\":\"16-Sep-2026 11:42:26\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 08, 2026, titled \\\"Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum\\\".\",\"category\":\"Press Release\",\"date\":\"08-Sep-2026 15:08:39\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08092026150801_Intimation_signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":5},{\"summary\":\"Change in Key Managerial Personnel Resignation of Chief Financial Officer.\",\"category\":\"Cessation\",\"date\":\"24-Sep-2026 12:43:36\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_24092026124110_Reg30Intimation_signed.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":4},{\"summary\":\"ALKEM: Alkem Laboratories Limited has informed the Exchange regarding Appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the company effective. September 15, 2026.\",\"category\":\"Appointment\",\"date\":\"15-Sep-2026 21:08:58\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_15092026210812_Reg_30.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5}],\"recent_news\":[{\"summary\":\"a press release dated September 16, 2026, titled \\\"Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.\\\".\",\"category\":\"Press Release\",\"date\":\"16-Sep-2026 11:42:26\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 08, 2026, titled \\\"Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum\\\".\",\"category\":\"Press Release\",\"date\":\"08-Sep-2026 15:08:39\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08092026150801_Intimation_signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":5},{\"summary\":\"Change in Key Managerial Personnel Resignation of Chief Financial Officer.\",\"category\":\"Cessation\",\"date\":\"24-Sep-2026 12:43:36\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_24092026124110_Reg30Intimation_signed.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":4},{\"summary\":\"ALKEM: Alkem Laboratories Limited has informed the Exchange regarding Appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the company effective. September 15, 2026.\",\"category\":\"Appointment\",\"date\":\"15-Sep-2026 21:08:58\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_15092026210812_Reg_30.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5}],\"promoter_pledge\":{\"summary\":\"An NSE promoter pledge\/encumbrance filing was identified, but the available filing text could not be reduced reliably to a concise current pledge figure.\",\"events\":[{\"summary\":\"le Marg, Worli, Mumbai - 400030 National Stock Exchange of India Limited \\\"Exchange Plaza\\\", 5th Floor, Plot No. C-1, Block G, Bandra - Kurla Complex, Bandra(E), Mumbai - 400 051 Symbol: ALKEM Sub: Declaration pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir\/ Madam, Pmsuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeove rs) Regulations, 2011, I, Basudeo N. Singh, promoter of Alkem Laboratories Limited, on behalf of all promoters\/ members of promoters group along with person acting in concert, hereby declare that we have not mad e any encumbrance, directly or indirectly, during the finan cial year 2025-26. The above is for your information and record. Thanking You Yours Sincerely, For and on behalf of Promot er(s) of Alkem Laboratories Limited ~(\\\\),?<:~\/ Basudeo N. Singh Promoter CC: Audit Committee Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013 Maharashtra, India\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"07-Apr-2026 14:30:02\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_06042026134202_Reg_3.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":49.7,\"public_pct\":50.3,\"fii_pct\":10.42,\"dii_pct\":22.63,\"mf_pct\":16.71,\"institutional_pct\":33.05,\"noninst_pct\":17.25,\"mf_scheme_count\":29,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Mutual Fund - Hdfc Mid-Cap Fund\",\"shares\":5706750,\"pct\":4.77},{\"name\":\"Icici Prudential Multi-Asset Fund\",\"shares\":4268472,\"pct\":3.57},{\"name\":\"Sbi Large &amp; Midcap Fund\",\"shares\":2383162,\"pct\":1.99},{\"name\":\"Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund\",\"shares\":2234434,\"pct\":1.87},{\"name\":\"Dsp Midcap Fund\",\"shares\":2132118,\"pct\":1.78}],\"period\":\"30-JUN-2026\",\"submission_date\":\"09-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":51.2,\"previous_fii_pct\":10.16,\"previous_dii_pct\":21.4,\"previous_mf_pct\":15.57,\"previous_institutional_pct\":31.56,\"previous_mf_scheme_count\":30,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Neutral\",\"target\":\"5770\",\"view_summary\":\"Alkem Labs Gets Target Price Hike After Q1 Beat, But Motilal Oswal Stays Neutral \u2014 Here's Why NDTV Profit\",\"headline\":\"Alkem Labs Gets Target Price Hike After Q1 Beat, But Motilal Oswal Stays Neutral \u2014 Here's Why\",\"published\":\"2026-08-17T07:00:00+00:00\",\"source\":\"NDTV Profit\"}],\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"JAYANTI SINHA\",\"side\":\"Sell\",\"quantity\":\"12,38,220\",\"price\":\"5,200\",\"value\":\"\u20b9643.87 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"ICICI PRUDENTIAL MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"9,03,527\",\"price\":\"5,200\",\"value\":\"\u20b9469.83 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"SAMPRADA&NANHAMATI SINGH FAMILY TRUST\",\"side\":\"Sell\",\"quantity\":\"5,50,000\",\"price\":\"5,200\",\"value\":\"\u20b9286.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"HDFC MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"5,09,615\",\"price\":\"5,200\",\"value\":\"\u20b9265.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"DSP MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"86,538\",\"price\":\"5,200\",\"value\":\"\u20b945.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"SOCIETE GENERALE\",\"side\":\"Buy\",\"quantity\":\"48,090\",\"price\":\"5,200\",\"value\":\"\u20b925.01 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"Nippon India Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"48090\",\"price\":\"5,200\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.01 Cr\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"Morgan Stanley Asia Singapore Pte\",\"side\":\"Buy\",\"quantity\":\"48090\",\"price\":\"5,200\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.01 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alkem Laboratories share price rose 1.11% to \u20b95,350.50 today. See why ALKEM is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":4630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Alkem Laboratories Share Price Today: Why ALKEM Is Rising 1.11% | 7 October 2026","_witty_meta_description":"Alkem Laboratories share price rose 1.11% to \u20b95,350.50 today. See why ALKEM is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Alkem Laboratories share price today","_witty_reason_label":"Stock-specific buying amid sector divergence","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[143],"class_list":["post-4631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-alkem"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=4631"}],"version-history":[{"count":6,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4631\/revisions"}],"predecessor-version":[{"id":5226,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/4631\/revisions\/5226"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/4630"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=4631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=4631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=4631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}